6744 Stock Overview
Feng Chi Biotech Corp. provides preimplantation genetic testing, prenatal testing, life science, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services.
Feng Chi Biotech Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$18.35|
|52 Week High||NT$26.50|
|52 Week Low||NT$18.20|
|1 Month Change||-4.43%|
|3 Month Change||-21.92%|
|1 Year Change||-27.18%|
|3 Year Change||-42.66%|
|5 Year Change||n/a|
|Change since IPO||-61.93%|
Recent News & Updates
|6744||TW Healthcare||TW Market|
Return vs Industry: 6744 underperformed the TW Healthcare industry which returned 8.5% over the past year.
Return vs Market: 6744 underperformed the TW Market which returned -19% over the past year.
|6744 Average Weekly Movement||5.0%|
|Healthcare Industry Average Movement||4.6%|
|Market Average Movement||5.1%|
|10% most volatile stocks in TW Market||8.3%|
|10% least volatile stocks in TW Market||2.5%|
Stable Share Price: 6744 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 6744's weekly volatility (5%) has been stable over the past year.
About the Company
Feng Chi Biotech Corp. provides preimplantation genetic testing, prenatal testing, life science, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services. The company is based in Taipei, Taiwan.
Feng Chi Biotech Fundamentals Summary
|6744 fundamental statistics|
Is 6744 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|6744 income statement (TTM)|
|Cost of Revenue||NT$106.21m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||1.38|
|Net Profit Margin||11.38%|
How did 6744 perform over the long term?See historical performance and comparison
6.8%Current Dividend Yield
Is 6744 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6744?
Other financial metrics that can be useful for relative valuation.
|What is 6744's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 6744's PE Ratio compare to its peers?
|6744 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
6615 Sofiva GenomicsLtd
6518 Concord Medical
6637 Medical Imaging
6744 Feng Chi Biotech
Price-To-Earnings vs Peers: 6744 is good value based on its Price-To-Earnings Ratio (13.3x) compared to the peer average (45.4x).
Price to Earnings Ratio vs Industry
How does 6744's PE Ratio compare vs other companies in the Asian Healthcare Industry?
Price-To-Earnings vs Industry: 6744 is good value based on its Price-To-Earnings Ratio (13.3x) compared to the Asian Healthcare industry average (17.4x)
Price to Earnings Ratio vs Fair Ratio
What is 6744's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||13.3x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 6744's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 6744 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 6744 (NT$18.35) is trading above our estimate of fair value (NT$17.01)
Significantly Below Fair Value: 6744 is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Feng Chi Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Feng Chi Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Feng Chi Biotech's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
How has Feng Chi Biotech performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6744 has high quality earnings.
Growing Profit Margin: 6744's current net profit margins (11.4%) are lower than last year (14.6%).
Past Earnings Growth Analysis
Earnings Trend: 6744's earnings have grown by 12.5% per year over the past 5 years.
Accelerating Growth: 6744's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 6744 had negative earnings growth (-18.5%) over the past year, making it difficult to compare to the Healthcare industry average (14.6%).
Return on Equity
High ROE: 6744's Return on Equity (9.5%) is considered low.
Discover strong past performing companies
How is Feng Chi Biotech's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 6744's short term assets (NT$278.3M) exceed its short term liabilities (NT$70.7M).
Long Term Liabilities: 6744 has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 6744 is debt free.
Reducing Debt: 6744 has not had any debt for past 5 years.
Debt Coverage: 6744 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 6744 has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Feng Chi Biotech current dividend yield, its reliability and sustainability?
Dividend Score 1/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
|Feng Chi Biotech Dividend Yield vs Market|
|Company (Feng Chi Biotech)||6.8%|
|Market Bottom 25% (TW)||2.5%|
|Market Top 25% (TW)||6.9%|
|Industry Average (Healthcare)||3.0%|
|Analyst forecast in 3 Years (Feng Chi Biotech)||n/a|
Notable Dividend: 6744's dividend (6.81%) is higher than the bottom 25% of dividend payers in the TW market (2.51%).
High Dividend: 6744's dividend (6.81%) is low compared to the top 25% of dividend payers in the TW market (6.91%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 6744 has been paying a dividend for less than 10 years.
Growing Dividend: 6744's dividend payments have increased, but the company has only paid a dividend for 2 years.
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (90.4%), 6744's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (92.9%), 6744's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Feng Chi Biotech has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Feng Chi Biotech Corp.'s employee growth, exchange listings and data sources
- Name: Feng Chi Biotech Corp.
- Ticker: 6744
- Exchange: TPEX
- Founded: NaN
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: NT$282.590m
- Shares outstanding: 15.40m
- Website: https://www.fcbiotech.com.tw
Number of Employees
- Feng Chi Biotech Corp.
- 1, No.5, Shaoxing North Street
- 5th Floor
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|6744||TPEX (Taipei Exchange)||Yes||Registered Common Shares||TW||TWD||Sep 2019|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/28 00:00|
|End of Day Share Price||2022/09/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.